| The human tumor microbiome is composed of tumor type–specific intracellular bacteria D Nejman, I Livyatan, G Fuks, N Gavert, Y Zwang, LT Geller, ... Science 368 (6494), 973-980, 2020 | 1506 | 2020 |
| Durvalumab, with or without tremelimumab, plus platinum–etoposide versus platinum–etoposide alone in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN … JW Goldman, M Dvorkin, Y Chen, N Reinmuth, K Hotta, D Trukhin, ... The Lancet Oncology 22 (1), 51-65, 2021 | 487 | 2021 |
| BRAF mutant lung cancer: programmed death ligand 1 expression, tumor mutational burden, microsatellite instability status, and response to immune check-point inhibitors E Dudnik, N Peled, H Nechushtan, M Wollner, A Onn, A Agbarya, ... Journal of Thoracic Oncology 13 (8), 1128-1137, 2018 | 213 | 2018 |
| p53 Attenuates cancer cell migration and invasion through repression of SDF-1/CXCL12 expression in stromal fibroblasts N Moskovits, A Kalinkovich, J Bar, T Lapidot, M Oren Cancer research 66 (22), 10671-10676, 2006 | 189 | 2006 |
| Stage-dependent differential expression of microRNAs in colorectal cancer: potential role as markers of metastatic disease MM Vickers, J Bar, I Gorn-Hondermann, N Yarom, M Daneshmand, ... Clinical & experimental metastasis 29, 123-132, 2012 | 154 | 2012 |
| Regulation of the inflammatory profile of stromal cells in human breast cancer: prominent roles for TNF-α and the NF-κB pathway C Katanov, S Lerrer, Y Liubomirski, L Leider-Trejo, T Meshel, J Bar, ... Stem cell research & therapy 6, 1-17, 2015 | 150 | 2015 |
| The interaction of CD4+ helper T cells with dendritic cells shapes the tumor microenvironment and immune checkpoint blockade response M Cohen, A Giladi, O Barboy, P Hamon, B Li, M Zada, A Gurevich-Shapiro, ... Nature cancer 3 (3), 303-317, 2022 | 122 | 2022 |
| Exhaled breath analysis for monitoring response to treatment in advanced lung cancer I Nardi-Agmon, M Abud-Hawa, O Liran, N Gai-Mor, M Ilouze, A Onn, J Bar, ... Journal of Thoracic Oncology 11 (6), 827-837, 2016 | 121 | 2016 |
| Effectiveness and safety of nivolumab in advanced non-small cell lung cancer: the real-life data E Dudnik, M Moskovitz, S Daher, S Shamai, E Hanovich, A Grubstein, ... Lung cancer 126, 217-223, 2018 | 114 | 2018 |
| Treatment characteristics and real-world progression-free survival in patients with unresectable stage III NSCLC who received durvalumab after chemoradiotherapy: findings from … N Girard, J Bar, P Garrido, MC Garassino, F McDonald, F Mornex, ... Journal of Thoracic Oncology 18 (2), 181-193, 2023 | 112 | 2023 |
| Rovalpituzumab tesirine as a maintenance therapy after first-line platinum-based chemotherapy in patients with extensive-stage–SCLC: results from the phase 3 MERU study ML Johnson, Z Zvirbule, K Laktionov, A Helland, BC Cho, V Gutierrez, ... Journal of Thoracic Oncology 16 (9), 1570-1581, 2021 | 103 | 2021 |
| Acute vascular events as a possibly related adverse event of immunotherapy: a single-institute retrospective study J Bar, G Markel, T Gottfried, R Percik, R Leibowitz-Amit, R Berger, T Golan, ... European Journal of Cancer 120, 122-131, 2019 | 91 | 2019 |
| Detection of lung cancer and EGFR mutation by electronic nose system D Shlomi, M Abud, O Liran, J Bar, N Gai-Mor, M Ilouze, A Onn, A Ben-Nun, ... Journal of Thoracic Oncology 12 (10), 1544-1551, 2017 | 87 | 2017 |
| Lymph node ratio may predict the benefit of postoperative radiotherapy in non–small-cell lung cancer D Urban, J Bar, B Solomon, D Ball Journal of Thoracic Oncology 8 (7), 940-946, 2013 | 86 | 2013 |
| L3 skeletal muscle index (L3SMI) is a surrogate marker of sarcopenia and frailty in non-small cell lung cancer patients D Portal, L Hofstetter, I Eshed, C Dan-Lantsman, T Sella, D Urban, A Onn, ... Cancer Management and Research, 2579-2588, 2019 | 76 | 2019 |
| Cancer cells suppress p53 in adjacent fibroblasts J Bar, R Feniger-Barish, N Lukashchuk, H Shaham, N Moskovits, ... Oncogene 28 (6), 933-936, 2009 | 75 | 2009 |
| Systemic dysregulation of CEACAM1 in melanoma patients G Markel, R Ortenberg, R Seidman, S Sapoznik, N Koren-Morag, ... Cancer Immunology, Immunotherapy 59, 215-230, 2010 | 73 | 2010 |
| Safety and efficacy of quavonlimab, a novel anti-CTLA-4 antibody (MK-1308), in combination with pembrolizumab in first-line advanced non-small-cell lung cancer R Perets, J Bar, DW Rasco, MJ Ahn, K Yoh, DW Kim, A Nagrial, ... Annals of Oncology 32 (3), 395-403, 2021 | 72 | 2021 |
| Repression of the MSP/MST-1 gene contributes to the antiapoptotic gain of function of mutant p53 A Zalcenstein, L Weisz, P Stambolsky, J Bar, V Rotter, M Oren Oncogene 25 (3), 359-369, 2006 | 70 | 2006 |
| Attenuation of the p53 response to DNA damage by high cell density J Bar, E Cohen-Noyman, B Geiger, M Oren Oncogene 23 (12), 2128-2137, 2004 | 66 | 2004 |